|
|
|
|
An experienced industry leader shares insights on how biosimilars are reshaping healthcare through scale, manufacturing discipline, supply reliability, and long‑term commercial strategy.
|
|
|
|
|
As biologics manufacturing globalizes, companies must balance cost, capacity, risk, and control when choosing between European and Asian supply bases for clinical and commercial success.
|
|
|
|
|
Platform biotech companies face critical choices on partnering, licensing, or selling technology—decisions that shape focus, valuation, and long‑term success beyond scientific innovation alone.
|
|
|
|
|
|
|
Advanced lipid nanoparticle strategies are transforming RNA therapeutics by enabling faster optimization, precise tissue targeting, and access to biological targets once considered unreachable.
|
|
|
|
|
A strategic approach to divestments and acquisitions helps biopharma organizations realign portfolios, accelerate growth, and connect the right assets with the right partners globally.
|
|
|
|
|
A unified global model streamlines biologics from discovery to commercial supply, integrating development, manufacturing, advanced modalities, and flexible partnerships worldwide.
|
|
|
